Bringing LSPR Nanotechnology to POC and Mobile Diagnostics
LamdaGen’s L’AuRa digital platform enables diagnostic sensitivities and precise quantitation at levels far beyond the expected. The Company’s patented plasmonic technologies (LSPR nanotechnology) produces highly robust biosensors in the form of nanostructured metallic thin-films that exhibit remarkable optical detection capabilities.
The Company’s L’AuRa Point of Care (POC) diagnostic platform enables an important performance shift away from traditional central laboratory analog testing to a rapid decentralized digital one. The L’AuRa testing system delivers rapid quantitative results in small mobile formats at the point of clinical need.
Chart above illustrates L’AuRa’s diagnostic performance as compared to ELISA and Lateral Flow
Flexible sensing membranes for monitoring bio-targets in perspiration: Read More >
Saliva-based Cortisol Assay: Read More ›
Troponin I (cTnI) Ap Note: Read More ›
L’AuRa Platform for Next-Generation Diagnostics: Read More ›
Enabling ultra-sensitive, rapid and precisely quantitative POC and mobile diagnostics
L’AuRa Digital Diagnostics
The L’AuRa diagnostic system is ideal for enabling high sensitivity, quantitative POC, mobile rapid testing.
LightPath™ S4
LamdaGen’s LightPath S4 system performs highly sensitive label-free, real-time monitoring and characterization of biomolecular interactions.
LSPR Biosensors
LamdaGen’s metallic thin-film LSPR-based Optical Biosensors for research and development in the areas of Life Science and Cleantech.